For US Health Care Professionals Only
![Novoeight® [Antihemophilic Factor (Recombinant)]](/content/dam/novonordisk/novoeightpro/global-images/logo-novoeight.png){kind=logo}
David, Dylan, and Malcolm live with hemophilia A.
The above table is not intended to compare the safety or efficacy of any of the products.
aDoes not include the EHL Esperoct (antihemophilic factor [recombinant], glycopegylated-exei).
bData current as of December 2, 2020.
Is Novoeight® right for your patients with hemophilia A? Qualifying patients can receive a trial prescription for 6 doses of Novoeight®.b
To learn more about our trial prescription program, please call 1-844-668-6732 to speak with a NovoSecure™ Specialist.
bPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.
When choosing a treatment that fits into their lives, Novoeight® patientsc consider more options than just half-life.
Hemophilia classification:
Severe hemophilia A
Bleeding pattern:
Spontaneous bleeds, typically in ankle or knee
Joint health:
Has minor joint damage
ABR:
1-2 joint bleeds
Current regimen:
Prophylaxis 3 times a week
Lifestyle considerations:
How Novoeight® may help:
Patients who appreciate the ability to store their product without refrigeration.
Individual results may vary.
Hemophilia classification:
Severe hemophilia A
Bleeding pattern:
Spontaneous muscle/joint bleeds; rarely experiences traumatic bleeds
Joint health:
Joint damage in the right knee
ABR:
1-2 joint bleeds
Current regimen:
Prophylaxis 3 times a week
Lifestyle considerations:
How Novoeight® may help:
Patients with a busy lifestyle.
Individual results may vary.
Hemophilia classification:
Moderate hemophilia A
Bleeding pattern:
Sporadic epistaxis (varied severity)
Joint health:
Not many problems with joints
ABR:
3 spontaneous bleeds
Current regimen:
On-demand
Lifestyle considerations:
How Novoeight® may help:
Patients without frequent bleeding episodes who achieve good control with a standard half-life rFVIII.
Individual results may vary.
cProfiles described are for illustrative purposes only; they are not those of actual patients.
The efficacy of Novoeight® is proven in clinical trials.12-14
Novoeight® was shown to be safe in clinical studies.1,12,13
Novoeight® offers higher temperature stability to fit into their lives.1
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.
Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.
If you like the efficacy and fixed dosing of Novoeight® (antihemophilic factor, recombinant), take a look at Esperoct® for your hemophilia A patients. With a longer half-life across age groups than standard half-life FVIII products, Esperoct® could be right for your patients.1,a,b
Please click here for Esperoct® Prescribing Information
Please click here for Novoeight® Prescribing Information
aA phase 1, open-label study evaluated the safety and pharmacokinetic properties of Esperoct® in 26 PTPs. Patients received a single dose of 25, 50, or 75 IU/kg of their previous SHL product (pdFVIII or rFVIII), followed by the same dose of Esperoct®. To allow for comparison, all results were adjusted to a 50 IU/kg dose of each product.1
bIn a phase 3 study of children (aged <12 years) a single-dose PK comparison was performed in 27 children between previous SHL products and Esperoct® at the same administered dose prior to the start of routine prophylaxis. Half-life comparison is based upon the estimated half-life derived from a population-based model. During the main phase, 68 children received prophylaxis at an average dose of approximately 65 IU/kg twice weekly for 26 weeks.2
References:
Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.
References
